Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Irene Casalin, Alessandra Cappellini, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Antonio Curti, Carlo Finelli

Blood (2022) 140 (Supplement 1): 6905–6906.

https://doi.org/10.1182/blood-2022-163628

Published: 2022

Journal Articles

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Valentina Indio, Annalisa Astolfi, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Andrea Pession, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Carlo Finelli

Blood (2021) 138 (Supplement 1): 3673.

https://doi.org/10.1182/blood-2021-149183

Published: 2021

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Alessia De Stefano, BSc, Valentina Indio, PhD, Annalisa Astolfi, PhD, Andrea Pellagatti, Stefano Ratti, MD, Miriam Fogli, PhD, Sarah Parisi, MDPhD, Andrea Pession, Michele Cavo, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, Carlo Finelli

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136942

Published: 2020

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2018) 132 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2018-99-117714

Published: 2018

Journal Articles

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Y Follo, PhD, Andrea Pellagatti, PhD, Richard N Armstrong, PhD, Stefano Ratti, MD, Sara Mongiorgi, PhD, Annalisa Astolfi, PhD, Valentina Indio, PhD, Cristina Clissa, MD PhD, Domenico Russo, MD, Marco Gobbi, MD, Marilena Barraco, PhD, Sarah Parisi, MD PhD, Andrea Pession, MD, Michele Cavo, MD, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, PhD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 5299.

https://doi.org/10.1182/blood.V130.Suppl_1.5299.5299

Published: 2017

Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2016) 128 (22): 3169.

https://doi.org/10.1182/blood.V128.22.3169.3169

Published: 2016

Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD

Blood (2016) 128 (22): 5091.

https://doi.org/10.1182/blood.V128.22.5091.5091

Published: 2016

Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Blood (2015) 126 (23): 2871.

https://doi.org/10.1182/blood.V126.23.2871.2871

Published: 2015

Journal Articles

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Matilde Y Follo, PhD, Carlo Finelli, Cristina Clissa, M.D., Sara Mongiorgi, PhD, Carmen Baldazzi, Marta Stanzani, MD, PhD, Michele Baccarani, MD, Lucio Cocco, MD

Blood (2013) 122 (21): 5227.

https://doi.org/10.1182/blood.V122.21.5227.5227

Published: 2013

Journal Articles

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Matilde Y Follo, PhD, Carlo Finelli, MD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Carla Filì, MD, Costanza Bosi, MD, Marilisa Quaranta, PhD, Stefania Paolini, MD, Anna Maria Billi, PhD, Marco Gobbi, MD, Michele Baccarani, MD, Domenico Russo, Giovanni Martinelli, MD, Lucia Manzoli, MD, Lucio Cocco, MD

Blood (2012) 120 (21): 1289.

https://doi.org/10.1182/blood.V120.21.1289.1289

Published: 2012

Journal Articles

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Carlo Finelli, M.D., Cristina Clissa, M.D., Maria Teresa Voso, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gianluca Gaidano, MD, PhD, Monica Crugnola, M.D., Maria Benedetta Giannini, M.D., Costanza Bosi, MD, Virginia Naso, MD, Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Giovanni Martinelli, Lucio Cocco, MD, Michele Baccarani, MD

Blood (2012) 120 (21): 4951.

https://doi.org/10.1182/blood.V120.21.4951.4951

Published: 2012

Journal Articles

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Matilde Y Follo, PhD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Francesca Chiarini, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, PhD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2011) 118 (21): 4635.

https://doi.org/10.1182/blood.V118.21.4635.4635

Published: 2011

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Francesca Chiarini, BS, Stefania Paolini, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Lucia Manzoli, MD, Alberto M. Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD, PhD

Blood (2009) 114 (22): 2384.

https://doi.org/10.1182/blood.V114.22.2384.2384

Published: 2009

Journal Articles

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

Carlo Finelli, MD, Matilde Y. Follo, PhD, Costanza Bosi, MD, Sara Mongiorgi, BS, Cristina Clissa, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Alberto M. Martelli, MD, PhD, Lucio Cocco, MD, PhD

Blood (2007) 110 (11): 2448.

https://doi.org/10.1182/blood.V110.11.2448.2448

Published: 2007

NARROW

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only